Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 709 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pre-Treatment Biopsy Clear all
Completed Phase 3 Interventional Results available

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

NCT01374971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy
Drug · Procedure
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 4, 2026, 1:31 AM EDT
Active, not recruiting No phase listed Observational

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

NCT04541030
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

NCT01023477
View directory record Official record
Conditions
Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
Interventions
Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy
Drug · Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 4, 2026, 1:31 AM EDT
Terminated Phase 1 Interventional Results available

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT02608229
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
BVD-523, Nab-paclitaxel, Gemcitabine, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 4, 2026, 1:31 AM EDT
Completed No phase listed Observational

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

NCT02781272
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1 Interventional Results available

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 4, 2026, 1:31 AM EDT
Not yet recruiting Phase 2 Interventional

Investigating Pre-Procedural Anxiety and Effect of Analgesia on Intrauterine Device Placement and Endometrial Biopsy

NCT07031206
View directory record Official record
Conditions
Anxiety, Pain
Interventions
Paracervical block- Lidocaine without epinephrine, Benzocaine Gel applied to the cervix, Hydroxyzine Hydrochloride
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 4, 2026, 1:31 AM EDT
Terminated Not applicable Interventional

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

NCT02464904
View directory record Official record
Conditions
Mesothelioma
Interventions
Cryotherapy, Control
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 4, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional Results available

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

NCT00064987
View directory record Official record
Conditions
Hypogonadism, Kallmann Syndrome
Interventions
Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH)
Procedure · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 4, 2026, 1:31 AM EDT
Recruiting No phase listed Observational

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

NCT05406232
View directory record Official record
Conditions
Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Radiation Therapy
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1 Interventional Results available

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraductal arm, Intravenous arm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 4, 2026, 1:31 AM EDT
Withdrawn Not applicable Interventional

Study to Assess Breast Sensation Before and After Breast Cancer Treatment

NCT02817607
View directory record Official record
Conditions
Breast Reconstruction, Ductal Carcinoma In-situ
Interventions
Sensory testing and Biopsy
Procedure
Lead sponsor
Duke University
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 4, 2026, 1:31 AM EDT
Active, not recruiting Phase 2 Interventional

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

NCT01203839
View directory record Official record
Conditions
Breast Cancer
Interventions
multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 4, 2026, 1:31 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

NCT05554341
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nilotinib Hydrochloride Monohydrate, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
124
States / cities
Birmingham, Alabama • Kingman, Arizona • Palo Alto, California + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

NCT03086642
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Talimogene laherparepvec
Drug
Lead sponsor
Karie D. Runcie, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 2 Interventional

Topical Chemoprevention of Skin Cancer Biomarkers

NCT02636569
View directory record Official record
Conditions
Non-melanoma Skin Cancer
Interventions
topical diclofenac daily, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 4, 2026, 1:31 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 4 Interventional

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

NCT03333655
View directory record Official record
Conditions
Neoplasms
Interventions
Biopsy
Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Not applicable Interventional

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

NCT00199862
View directory record Official record
Conditions
Colorectal Neoplasms, Colorectal Cancer, Colorectal Tumor, COlorectal Carcinoma
Interventions
Iodine-124 labeled humanized A33 (antibody)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 1 Interventional

MSC for Occlusive Disease of the Kidney

NCT01840540
View directory record Official record
Conditions
Atherosclerotic Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Hypertension
Interventions
Arterial infusion of autologous mesenchymal stem cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985
View directory record Official record
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 4, 2026, 1:31 AM EDT
Completed Phase 2 Interventional Results available

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

NCT01652196
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
Biological · Drug · Other + 2 more
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 4, 2026, 1:31 AM EDT